Abstract

Zika virus (ZIKV) emerged on a global scale and no licensed vaccine ensures long-lasting anti-ZIKV immunity. Here we report the design and comparative evaluation of four replication-deficient chimpanzee adenoviral (ChAdOx1) ZIKV vaccine candidates comprising the addition or deletion of precursor membrane (prM) and envelope, with or without its transmembrane domain (TM). A single, non-adjuvanted vaccination of ChAdOx1 ZIKV vaccines elicits suitable levels of protective responses in mice challenged with ZIKV. ChAdOx1 prME ∆TM encoding prM and envelope without TM provides 100% protection, as well as long-lasting anti-envelope immune responses and no evidence of in vitro antibody-dependent enhancement to dengue virus. Deletion of prM and addition of TM reduces protective efficacy and yields lower anti-envelope responses. Our finding that immunity against ZIKV can be enhanced by modulating antigen membrane anchoring highlights important parameters in the design of viral vectored ZIKV vaccines to support further clinical assessments.

Details

Title
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors
Author
López-Camacho, César 1   VIAFID ORCID Logo  ; Abbink, Peter 2   VIAFID ORCID Logo  ; Larocca, Rafael A 2   VIAFID ORCID Logo  ; Dejnirattisai, Wanwisa 3 ; Boyd, Michael 2 ; Badamchi-Zadeh, Alex 2 ; Wallace, Zoë R 4 ; Doig, Jennifer 5 ; Ricardo Sanchez Velazquez 5   VIAFID ORCID Logo  ; Roberto Dias Lins Neto 6   VIAFID ORCID Logo  ; Coelho, Danilo F 6   VIAFID ORCID Logo  ; Young Chan Kim 1   VIAFID ORCID Logo  ; Donald, Claire L 5   VIAFID ORCID Logo  ; Owsianka, Ania 5 ; De Lorenzo, Giuditta 5 ; Kohl, Alain 5 ; Gilbert, Sarah C 7   VIAFID ORCID Logo  ; Dorrell, Lucy 4 ; Mongkolsapaya, Juthathip 8 ; Patel, Arvind H 5   VIAFID ORCID Logo  ; Screaton, Gavin R 9 ; Barouch, Dan H 2 ; Hill, Adrian V S 7   VIAFID ORCID Logo  ; Reyes-Sandoval, Arturo 1   VIAFID ORCID Logo 

 The Jenner Institute, Nuffield Department of Medicine, University of Oxford, The Henry Wellcome Building for Molecular Physiology, Oxford, UK 
 Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA 
 Division of Immunology and Inflammation, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK 
 Nuffield Department of Medicine and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK 
 MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow,, Scotland, UK 
 Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, Brazil 
 The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK 
 Division of Immunology and Inflammation, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK; Dengue Hemorrhagic Fever Research Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand 
 Division of Medical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK 
Pages
1-11
Publication year
2018
Publication date
Jun 2018
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2058241336
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.